<DOC>
	<DOCNO>NCT02368288</DOCNO>
	<brief_summary>The aim interferon therapy HBeAg positive chronic hepatitis B make patient obtain immune control hepatitis B virus define occur HBeAg seroconversion HBsAg loss sustain viral response treatment . However target could get patient keep HBV DNA positive interferon treatment offend relapse withdraw treatment . In trail , Nucleoside ( acid ) analogue ( NA ) add patient HBV DNA load ≥1000copies/ml 6 month interferon treatment , efficacy combine therapy evaluate rate HBeAg seroconversion HBsAg loss 48 week combine therapy , compare control group .</brief_summary>
	<brief_title>Efficacies Entecavir Add HBeAg Positive Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment</brief_title>
	<detailed_description>HBeAg positive patient HBV DNA load ≥1000copies/ml 6 month peginterferon alpha 2a treatment enrol randomize two group , intervention group , patient receive entecavir combine peginterferon alpha 2a ( PEG-IFN a-2a ) treatment 48 week follow 24 week . Patients control group continue treat PEG-IFN a-2a 48 week follow 24 week . Serum HBV DNA load , HBsAg/anti-HBs level , HBeAg/anti-HBe test enrollment every 3 month treatment course . Parameters Liver kidney function , liver ultrasound examination test interval 1-3 month . The efficacy combine therapy evaluate rate HBeAg seroconversion HBsAg loss 48 week combine therapy , compare control group .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>HBeAg positive patient HBV DNA load ≥1000copies/ml 6 month peginterferon a2a treatment Active consumption alcohol and/or drug Coinfection human immunodeficiency virus , hepatitis C virus , hepatitis D virus History autoimmune hepatitis Psychiatric disease Evidence neoplastic disease liver</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>chronic hepatitic B</keyword>
	<keyword>peginterferon</keyword>
	<keyword>HBsAg</keyword>
	<keyword>entecavir</keyword>
</DOC>